Capacity Limits in Australian Health Care System Could Delay Widespread Access to a Future Alzheimer's Treatment
Nov 11, 2019
This report assesses the magnitude of the potential health system challenges in the diagnosis and treatment of early-stage Alzheimer's disease in Australia, given the hypothetical availability of a disease-modifying therapy. It uses a simulation model to compare the expected number of patients with the capacity of the health system and assess three possible constraints: visits to dementia specialists, biomarker testing, and infusion delivery.
Does not include Appendix
|PDF file||0.6 MB|
|PDF file||0.4 MB|
Disease-modifying therapies to prevent or delay the progression of Alzheimer's disease (AD) are under clinical investigation. AD is the leading cause of dementia, and the more than 800,000 Australians with mild cognitive impairment in 2018 could potentially benefit from a therapy that reduces the risk of progression to dementia.
This report assesses the magnitude of the potential health system challenges in the diagnosis and treatment of early-stage Alzheimer's disease in Australia, given the hypothetical availability of a disease-modifying therapy. The authors use a simulation model to compare the expected number of patients with the capacity of the health system and assess three possible constraints: visits to dementia specialists, biomarker testing, and infusion delivery. They find that the most pressing constraint is the availability of dementia specialists to evaluate and diagnose patients, followed by average waiting times of a few months for biomarker testing to confirm diagnosis and infusion delivery of the treatment. By eliminating wait lists that delay people from accessing the therapy, they estimate that 54,000 Australians would not progress from mild cognitive impairment due to AD to Alzheimer's dementia between 2023 and 2033.
Although the analysis includes simplifying assumptions and is not predictive of the future, the intention is to facilitate discussions among stakeholders. Multiple stakeholders would need to coordinate reimbursement, workforce and capacity planning, and outreach efforts to ensure that people with early-stage AD would have timely access if a therapy becomes available.
This research was sponsored by Biogen and conducted by the Access and Delivery Program in within RAND Health Care.
This report is part of the RAND Corporation Research report series. RAND reports present research findings and objective analysis that address the challenges facing the public and private sectors. All RAND reports undergo rigorous peer review to ensure high standards for research quality and objectivity.
This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.